Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

References

• Shivalkar S, Pingali MS, Verma A, et al. Outbreak of COVID-19: a detailed overview and its consequences. Adv Exp Med Biol. 2021;1353:23–45.
   PubMedGoogle Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• Ibrahim AE, Magdy M, Khalaf EM, et al. Teledermatology in the time of COVID-19. Int J Clin Pract. 2021;75(12):e15000. doi:10.1111/ijcp.15000
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Annunziata MC, et al. Maskne prevalence and risk factors during the COVID −19 pandemic. J Eur Acad Dermatol Venereol. 2022;36(9):e678–e680. doi:10.1111/jdv.18248
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fornaro L, et al. The impact of COVID-19 pandemic on nonmelanoma skin cancers: report of a Southern Italy referral centre [published online ahead of print, 2022 Jun 21]. Clin Exp Dermatol. 2022. doi:10.1111/ced.15307
   Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, et al. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’. Clin Exp Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Tull MT, Edmonds KA, Scamaldo KM, et al. Psychological outcomes associated with stay-at-home orders and the perceived impact of COVID-19 on daily life. Psychiatry Res. 2020;289:113098. doi:10.1016/j.psychres.2020.113098
   PubMed Web of Science ®Google Scholar
• Villani A, Scalvenzi M, Fabbrocini G, et al. Effects of COVID-19 pandemic on malignant melanoma diagnosis. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18545
   Web of Science ®Google Scholar
• Picone V, Gallo L, Fabbrocini G, et al. Impact of COVID-19 pandemic and the use of telemedicine on the diagnosis and treatment of tinea corporis: an experience of Southern Italy center. Dermatol Ther;2022. e15789. doi:10.1111/dth.15789
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, et al. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Hudson A, Montelpare WJ. Predictors of vaccine hesitancy: implications for COVID-19 public health messaging. Int J Environ Res Public Health. 2021;18(15):8054. doi:10.3390/ijerph18158054
   PubMed Web of Science ®Google Scholar
• Olusanya OA, Bednarczyk RA, Davis RL, et al. Addressing parental vaccine hesitancy and other barriers to childhood/adolescent vaccination uptake during the coronavirus (COVID-19) pandemic. Front Immunol. 2021;12:663074. doi:10.3389/fimmu.2021.663074
   PubMed Web of Science ®Google Scholar
• Sharif N, Alzahrani KJ, Ahmed SN, et al. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170. doi:10.3389/fimmu.2021.714170
   PubMed Web of Science ®Google Scholar
• COVID-19 dashboard by the Center For Systems Science And Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html. Accessed September 22, 2022.
   Google Scholar
• European Medicines Agency. COVID-19 vaccines: authorised. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised. Accessed November 2, 2022.
   Google Scholar
• COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed September 11, 2022.
   Google Scholar
• Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–1399. doi:10.1001/jama.2021.15072
   PubMed Web of Science ®Google Scholar
• Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (pfizer-biontech and moderna): update from the advisory committee on immunization practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094–1099. doi:10.15585/mmwr.mm7032e4
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RWJ, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906
   PubMed Web of Science ®Google Scholar
• Sun Q, Fathy R, McMahon DE, et al. COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide. Dermatol Clin. 2021;39(4):653–673. doi:10.1016/j.det.2021.05.016
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther;2022. 1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Camela E, Potestio L, Ruggiero A, et al. Towards personalized medicine in psoriasis: current progress. Psoriasis. 2022;12:231–250. doi:10.2147/PTT.S328460
   PubMed Web of Science ®Google Scholar
• Tran TNA, Nguyen TTP, Pham NN, et al. New onset of psoriasis following COVID −19 vaccination. Dermatol Ther. 2022;35(8):e15590. doi:10.1111/dth.15590
   PubMed Web of Science ®Google Scholar
• Ouni N, Korbi M, Chahed F, et al. New-onset guttate psoriasis following coronavirus disease 2019 vaccination: about two cases. Dermatol Ther. 2022;35:e15617. doi:10.1111/dth.15617
   PubMed Web of Science ®Google Scholar
• Romagnuolo M, Pontini P, Muratori S, et al. De novo annular pustular psoriasis following mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2022;36:e603–e605. doi:10.1111/jdv.18114
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Battista T, et al. Reply to ‘Nail psoriasis: a rare mRNA COVID-19 vaccine reaction’ by Lamberti A et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18537
   Web of Science ®Google Scholar
• Ricardo JW, Lipner SR. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021;17:18–20. doi:10.1016/j.jdcr.2021.09.009
   PubMedGoogle Scholar
• Pesqué D, Lopez-Trujillo E, Marcantonio O, et al. New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin? J Eur Acad Dermatol Venereol. 2022;36:e80–e81. doi:10.1111/jdv.17690
   PubMed Web of Science ®Google Scholar
• Huang Y-W, Tsai T-F. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med. 2021;8:812010. doi:10.3389/fmed.2021.812010
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Tsentemeidou A, Bakirtzi K, et al. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021;35(12):e857–e859. doi:10.1111/jdv.17582
   PubMed Web of Science ®Google Scholar
• Koumaki D, Krueger-Krasagakis S-E, Papadakis M, et al. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. J Eur Acad Dermatol Venereol. 2022;36:e411–e415. doi:10.1111/jdv.17965
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Gallo L, et al. Reply to “Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al. J Eur Acad Dermatol Venereol. 2022;36(1):e11–e13. doi:10.1111/jdv.17665
   PubMed Web of Science ®Google Scholar
• Durmaz I, Turkmen D, Altunisik N, et al. Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID −19 vaccine: a report of three cases. Dermatol Ther. 2022;35:e15331. doi:10.1111/dth.15331
   PubMed Web of Science ®Google Scholar
• Tran TB, Pham NTU, Phan HN, et al. Generalized erythrodermic psoriasis triggered by vaccination against severe acute respiratory syndrome coronavirus 2. Dermatol Ther. 2022;35(6):e15464. doi:10.1111/dth.15464
   PubMed Web of Science ®Google Scholar
• Nagrani P, Jindal R, Goyal D. Onset / flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca / Covishield): report of two cases. Dermatol Ther. 2021;34(5):1–2. doi:10.1111/dth.15085
   Web of Science ®Google Scholar
• Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022;36:e330–e332. doi:10.1111/jdv.17918
   PubMed Web of Science ®Google Scholar
• Bostan E, Elmas L, Yel B, Yalici‐Armagan B. Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases. Dermatol Ther. 2021;34(6):1–3. doi:10.1111/dth.15110
   Web of Science ®Google Scholar
• Pavia G, Gargiulo L, Spinelli F, et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol. 2022;36:e502–e505. doi:10.1111/jdv.18032
   PubMed Web of Science ®Google Scholar
• Durmus O, Akdogan N, Karadag O, et al. Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis. Dermatol Ther. 2022;35(5):e15363. doi:10.1111/dth.15363
   PubMed Web of Science ®Google Scholar
• Fang W-C, Chiu L-W, Hu -SC-S. Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. J Dermatol. 2021;48:e566–e567. doi:10.1111/1346-8138.16137
   PubMed Web of Science ®Google Scholar
• Krajewski PK, Matusiak Ł, Szepietowski JC. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021;35:e632–e634. doi:10.1111/jdv.17449
   PubMed Web of Science ®Google Scholar
• Trepanowski N, Coleman EL, Melson G, et al. Erythrodermic psoriasis after COVID-19 vaccination. JAAD Case Rep. 2022;28:123–126. doi:10.1016/j.jdcr.2022.07.041
   PubMedGoogle Scholar
• Mieczkowska K, Kaubisch A, McLellan BN. Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. Dermatol Ther. 2021;34(5):10–11. doi:10.1111/dth.15055
   Web of Science ®Google Scholar
• Lopez ED, Javed N, Upadhyay S, et al. Acute exacerbation of psoriasis after COVID-19 Pfizer vaccination. Proceedings (Baylor University. Medical Center); 2022: 199–201.
   Google Scholar
• Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1–3. doi:10.1016/j.jdcr.2021.08.035
   PubMedGoogle Scholar
• Song WJ, Lim Y, Jo SJ. De novo guttate psoriasis following coronavirus disease 2019 vaccination. J Dermatol. 2022;49:e30–e31. doi:10.1111/1346-8138.16203
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Watabe D, Amano H. Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA COVID-19 vaccine during risankizumab treatment. J Dermatol. 2022. doi:10.1111/1346-8138.16505
   Web of Science ®Google Scholar
• Nia AM, Silva MM, Spaude J, et al. Erythrodermic psoriasis eruption associated with SARS-CoV −2 vaccination. Dermatol Ther. 2022;35:e15380. doi:10.1111/dth.15380
   PubMed Web of Science ®Google Scholar
• Frioui R, Chamli A, Zaouak A, et al. A case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine. Dermatol Ther. 2022;35:e15444. doi:10.1111/dth.15444
   PubMed Web of Science ®Google Scholar
• Cortonesi G, Orsini C, Rubegni P, et al. New-onset psoriasis after Comirnaty (BNT162b2, BioNTech /Pfizer) vaccine successfully treated with ixekizumab. Dermatol Ther. 2022;35:e15606. doi:10.1111/dth.15606
   PubMed Web of Science ®Google Scholar
• Lehmann M, Schorno P, Hunger RE, et al. New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021;35(11):e752–e755. doi:10.1111/jdv.17561
   PubMed Web of Science ®Google Scholar
• Elamin S, Hinds F, Tolland J. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin Exp Dermatol. 2022;47:153–155. doi:10.1111/ced.14895
   PubMed Web of Science ®Google Scholar
• Wei N, Kresch M, Elbogen E, et al. New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Rep. 2022;19:74–77. doi:10.1016/j.jdcr.2021.11.016
   PubMedGoogle Scholar
• Lamberti A, Lora V, Graceffa D, et al. Nail psoriasis: a rare mRNA COVID −19 vaccine reaction. J Eur Acad Dermatol Venereol. 2022;36(10). doi:10.1111/jdv.18255
   Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, et al. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34(5):e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther;2022. 1–18. doi:10.1080/14712598.2022.2089020
   Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022. doi:10.1111/ced.15395
   Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022. doi:10.1111/ced.15336
   Web of Science ®Google Scholar
• Usatine RP, Tinitigan M. Diagnosis and treatment of lichen planus. Am Fam Physician. 2011;84(1):53–60.
   PubMed Web of Science ®Google Scholar
• Merhy R, Sarkis A-S, Kaikati J, et al. New-onset cutaneous lichen planus triggered by COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e729–e730. doi:10.1111/jdv.17504
   PubMed Web of Science ®Google Scholar
• Camela E, Guerrasio G, Patruno C, et al. Reply to “New-onset cutaneous lichen planus triggered by COVID-19 vaccination” by Merhy et al. J Eur Acad Dermatol Venereol. 2022;36:e249–e251. doi:10.1111/jdv.17866
   PubMed Web of Science ®Google Scholar
• Gamonal SBL, Gamonal ACC, Marques NCV, et al. Lichen planus and vitiligo occurring after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2. Dermatol Ther. 2022;35(5):e15422.
   PubMed Web of Science ®Google Scholar
• Alrawashdeh HM, Al-Habahbeh O, Naser AY, et al. Lichen planus eruption following oxford-AstraZeneca COVID-19 vaccine administration: a case report and review of literature. Cureus. 2022;14:e22669. doi:10.7759/cureus.22669
   PubMed Web of Science ®Google Scholar
• Shakoei S, Kalantari Y, Nasimi M, et al. Cutaneous manifestations following COVID-19 vaccination: a report of 25 cases. Dermatol Ther. 2022;35(8):e15651. doi:10.1111/dth.15651
   PubMed Web of Science ®Google Scholar
• Hiltun I, Sarriugarte J, Martínez-de-Espronceda I, et al. Lichen planus arising after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35:e414–e415. doi:10.1111/jdv.17221
   PubMed Web of Science ®Google Scholar
• Herzum A, Burlando M, Molle MF, et al. Lichen planus flare following COVID-19 vaccination: a case report. Clin Case Rep. 2021;9(12):e05092. doi:10.1002/ccr3.5092
   PubMed Web of Science ®Google Scholar
• Kato J, Kamiya T, Handa T, et al. Linear lichen planus after COVID-19 vaccination. Australas J Dermatol. 2022. doi:10.1111/ajd.13902
   Web of Science ®Google Scholar
• Diab R, Araghi F, Gheisari M, et al. Lichen planus and lichen planopilaris flare after COVID −19 vaccination. Dermatol Ther. 2022;35(3):e15283. doi:10.1111/dth.15283
   PubMed Web of Science ®Google Scholar
• Zagaria O, Villani A, Ruggiero A, et al. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Awada B, Abdullah L, Kurban M, et al. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine. J Cosmet Dermatol. 2022;21(3):883–885. doi:10.1111/jocd.14738
   PubMed Web of Science ®Google Scholar
• Picone V, Fabbrocini G, Martora L, et al. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
   Web of Science ®Google Scholar
• Hlaca N, Zagar T, Kastelan M, et al. New-onset lichen planus and lichen planus flare in elderly women after COVID −19 vaccination. J Cosmet Dermatol. 2022;21(9):3679–3681. doi:10.1111/jocd.15185
   PubMed Web of Science ®Google Scholar
• Zengarini C, Piraccini BM, La Placa M. Lichen Ruber Planus occurring after SARS-CoV-2 vaccination. Dermatol Ther. 2022;35:e15389. doi:10.1111/dth.15389
   PubMed Web of Science ®Google Scholar
• Masseran C, Calugareanu A, Caux F, et al. Extensive cutaneous lichen planus triggered by viral vector COVID-19 vaccination (ChAdOx1 nCoV-19). J Eur Acad Dermatol Venereol. 2022;36(4):e263–5. doi:10.1111/jdv.17899
   PubMed Web of Science ®Google Scholar
• Rerknimitr P, Puaratanaarunkon T, Wongtada C, et al. Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers. J Eur Acad Dermatol Venereol. 2022;36:e158–61. doi:10.1111/jdv.17761
   PubMed Web of Science ®Google Scholar
• Holmes GA, Desai M, Limone B, et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda university department of dermatology. JAAD Case Rep. 2021;16:53–57. doi:10.1016/j.jdcr.2021.07.038
   PubMedGoogle Scholar
• Leasure AC, Cowper SE, McNiff J, et al. Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):e716–e717. doi:10.1111/jdv.17494
   PubMed Web of Science ®Google Scholar
• Bekkali N, Allard T, Lengellé C, et al. [Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine]. Therapie. 2021;76:364–365. French. doi:10.1016/j.therap.2021.04.012
   PubMed Web of Science ®Google Scholar
• Larson V, Seidenberg R, Caplan A, et al. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID −19 vaccination. J Cutan Pathol. 2022;49(1):34–41. doi:10.1111/cup.14104
   PubMed Web of Science ®Google Scholar
• Potestio L, Napolitano M, Bennardo L, et al. Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. J Eur Acad Dermatol Venereol. 2022;36(6):e409–e411. doi:10.1111/jdv.17964
   PubMed Web of Science ®Google Scholar
• Niebel D, Wenzel J, Wilsmann-Theis D, et al. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines. Dermatopathol. 2021;8(4):463–476. doi:10.3390/dermatopathology8040049
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat;2022. 1–6. doi:10.1080/09546634.2022.2102121
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Genco L, et al. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
   PubMed Web of Science ®Google Scholar
• Cantelli M, Martora F, Patruno C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022;35(4):e15346. doi:10.1111/dth.15346
   PubMed Web of Science ®Google Scholar
• Alexander H, Patel NP. Response to Martora et al’s “Hidradenitis suppurativa flares following COVID-19 vaccination: a case series”. JAAD Case Rep. 2022;25:13–14. doi:10.1016/j.jdcr.2022.05.005
   PubMedGoogle Scholar
• Martora F, Picone V, Fabbrocini G, et al. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar
• Pakhchanian H, Raiker R, DeYoung C, et al. Evaluating the safety and efficacy of COVID −19 vaccination in patients with hidradenitis suppurativa. Clin Exp Dermatol. 2022;47:1186–1188. doi:10.1111/ced.15090
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Battista T, et al. Management of patients with hidradenitis suppurativa during COVID −19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID −19 vaccination in patients with hidradenitis suppurativa’. Clin Exp Dermatol. 2022;47(11):2026–2028. doi:10.1111/ced.15306
   PubMed Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, et al. “Covid arm”: abnormal side effect after Moderna COVID −19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Magen E, Yakov A, Green I, et al. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy Asthma Proc. 2022;43(1):30–36. doi:10.2500/aap.2022.43.210111
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study’. by Bawane J et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18341
   Web of Science ®Google Scholar
• Riad A, Pokorná A, Attia S, et al. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428. doi:10.3390/jcm10071428
   PubMed Web of Science ®Google Scholar
• Sidlow JS, Reichel M, Lowenstein EJ. Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients. JAAD Case Rep. 2021;14:13–16. doi:10.1016/j.jdcr.2021.05.018
   PubMedGoogle Scholar
• Peigottu MF, Ferreli C, Atzori MG, et al. Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series. Disease. 2021;9(3):58. doi:10.3390/diseases9030058
   PubMed Web of Science ®Google Scholar
• McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–121. doi:10.1016/j.jaad.2021.09.002
   PubMed Web of Science ®Google Scholar
• Fernandez-Nieto D, Hammerle J, Fernandez-Escribano M, et al. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. “COVID-arm”: a clinical and histological characterization. J Eur Acad Dermatol Venereol. 2021;35:e425–e427. doi:10.1111/jdv.17250
   PubMed Web of Science ®Google Scholar
• Bianchi L, Biondi F, Hansel K, et al. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing. Allergy. 2021;76(8):2605–2607. doi:10.1111/all.14839
   PubMed Web of Science ®Google Scholar
• Corbeddu M, Diociaiuti A, Vinci MR, et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series. J Eur Acad Dermatol Venereol. 2021;35:e483–e485. doi:10.1111/jdv.17268
   PubMed Web of Science ®Google Scholar
• Baraldi C, Boling LB, Patrizi A, et al. Unique case of urticarial skin eruptions after COVID-19 vaccination. Am J Dermatopathol. 2022;44:198–200. doi:10.1097/DAD.0000000000002036
   PubMed Web of Science ®Google Scholar
• Choi E, Liew CF, Oon HH. Cutaneous adverse effects and contraindications to COVID-19 vaccination; four cases and an illustrative review from an Asian country. Dermatol Ther. 2021;34:e15123. doi:10.1111/dth.15123
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Stingeni L, et al. Skin rashes after SARS-CoV-2 vaccine: which relationship if any? Immunity Inflamm Dis. 2021;(3):622–623. doi:10.1002/iid3.428
   PubMed Web of Science ®Google Scholar
• Burlando M, Herzum A, Cozzani E, et al. Acute urticarial rash after COVID-19 vaccination containing polysorbate 80. Clin Exp Vaccine Res. 2021;10(3):298–300. doi:10.7774/cevr.2021.10.3.298
   PubMed Web of Science ®Google Scholar
• Thomas J, Thomas G, Chatim A, et al. Chronic spontaneous urticaria after COVID-19 vaccine. Cureus. 2021;13(9):e18102.
   PubMed Web of Science ®Google Scholar
• Picone V, Napolitano M, Martora F, et al. Urticaria Relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: a single-center experience. Dermatol Ther;2022. e15838. doi:10.1111/dth.15838
   PubMed Web of Science ®Google Scholar
• Scollan ME, Breneman A, Kinariwalla N, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1–5. doi:10.1016/j.jdcr.2021.11.023
   PubMedGoogle Scholar
• Babadjouni A, Phong CH, Nguyen C, et al. COVID-19 vaccination related exacerbations of hair loss in patients with moderate to severe alopecia areata on systemic therapy. JAAD Case Rep. 2022;29:181–185. doi:10.1016/j.jdcr.2022.08.016
   PubMedGoogle Scholar
• Rossi A, Magri F, Michelini S, et al. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy. J Cosmet Dermatol. 2021;20(12):3753–3757. doi:10.1111/jocd.14581
   PubMed Web of Science ®Google Scholar
• Chen C-H, Chen Y-Y, Lan C-CE. Intractable alopecia areata following the second dose of COVID-19 vaccination: report of two cases. Dermatol Ther. 2022;35:e15689. doi:10.1111/dth.15689
   PubMed Web of Science ®Google Scholar
• Abdalla H, Ebrahim E. Alopecia areata universalis precipitated by SARS-CoV-2 vaccine: a case report and narrative review. Cureus. 2022;14:e27953. doi:10.7759/cureus.27953
   PubMed Web of Science ®Google Scholar
• Gamonal SBL, Marques NCV, Pereira HMB, et al. New-onset systemic lupus erythematosus after ChAdOX1 nCoV-19 and alopecia areata after BNT162b2 vaccination against SARS-CoV-2. Dermatol Ther. 2022;35:e15677. doi:10.1111/dth.15677
   PubMed Web of Science ®Google Scholar
• Ho JD, McNish A, McDonald L, et al. Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222). JAAD Case Rep. 2022;25:4–8. doi:10.1016/j.jdcr.2022.05.002
   PubMedGoogle Scholar
• Su H-A, Juan C-K, Chen Y-C. Alopecia areata following ChAdOx1 nCoV-19 vaccination (Oxford/AstraZeneca). J Formosan Med Assoc. 2022;121(10):2138–2140. doi:10.1016/j.jfma.2022.03.006
   PubMed Web of Science ®Google Scholar
• Gallo G, Mastorino L, Tonella L, et al. Alopecia areata after COVID-19 vaccination. Clin Exp Vaccine Res. 2022;11(1):129–132. doi:10.7774/cevr.2022.11.1.129
   PubMed Web of Science ®Google Scholar
• May Lee M, Bertolani M, Pierobon E, et al. Alopecia areata following COVID −19 vaccination: vaccine-induced autoimmunity? Int J Dermatol. 2022;61:634–635. doi:10.1111/ijd.16113
   PubMed Web of Science ®Google Scholar
• Essam R, Ehab R, Al-Razzaz R, et al. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? J Cosmet Dermatol. 2021;20:3727–3729. doi:10.1111/jocd.14459
   PubMed Web of Science ®Google Scholar
• Nguyen B, Tosti A. Alopecia areata after COVID-19 infection and vaccination: a cross-sectional analysis. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18491
   Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, et al. Reply to ‘Development of severe pemphigus vulgaris following SARS-CoV −2 vaccination with BNT162b2’ by Solimani et al. J Eur Acad Dermatol Venereol. 2022;36(10):e750–e751. doi:10.1111/jdv.18302
   PubMed Web of Science ®Google Scholar
• Zou H, Daveluy S. Pemphigus vulgaris after COVID-19 infection and vaccination. J Am Acad Dermatol. 2022;87(3):709–710. doi:10.1016/j.jaad.2022.05.013
   PubMed Web of Science ®Google Scholar
• Gui H, Young PA, So JY, et al. New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: a report of 2 cases. JAAD Case Rep. 2022;27:94–98. doi:10.1016/j.jdcr.2022.07.002
   PubMedGoogle Scholar
• Rouatbi J, Aounallah A, Lahouel M, et al. Two cases with new onset of Pemphigus Foliaceus after SARS-CoV-2 vaccination. Dermatol ther. 2022;e15827. doi:10.1111/dth.15827
   PubMed Web of Science ®Google Scholar
• Aryanian Z, Balighi K, Azizpour A, et al. Coexistence of pemphigus vulgaris and lichen planus following COVID-19 vaccination. Case Rep Dermatol Med. 2022;2022:2324212. doi:10.1155/2022/2324212
   PubMedGoogle Scholar
• Koutlas IG, Camara R, Argyris PP, et al. Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine. Oral Dis. 2021. doi:10.1111/odi.14089
   PubMed Web of Science ®Google Scholar
• Knechtl GV, Seyed Jafari SM, Berger T, et al. Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient. J Eur Acad Dermatol Venereol. 2022;36(4):e251–e253. doi:10.1111/jdv.17868
   PubMed Web of Science ®Google Scholar
• Ong SK, Darji K, Chaudhry SB. Severe flare of pemphigus vulgaris after first dose of COVID-19 vaccine. JAAD Case Rep. 2022;22:50–52. doi:10.1016/j.jdcr.2022.01.027
   PubMedGoogle Scholar
• Yıldırıcı Ş, Yaylı S, Demirkesen C, et al. New onset of pemphigus foliaceus following BNT162b2 vaccine. Dermatol Ther. 2022;35:e15381. doi:10.1111/dth.15381
   PubMed Web of Science ®Google Scholar
• Singh A, Bharadwaj SJ, Chirayath AG, et al. Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature. J Cosmet Dermatol. 2022;21(6):2311–2314. doi:10.1111/jocd.14945
   PubMed Web of Science ®Google Scholar
• Norimatsu Y, Yoshizaki A, Yamada T, et al. Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV −2 vaccination. J Dermatol. 2022. doi:10.1111/1346-8138.16539
   PubMed Web of Science ®Google Scholar
• Agharbi F-Z, Basri G, Chiheb S. Pemphigus vulgaris following second dose of mRNA-(Pfizer-BioNTech) COVID-19 vaccine. Dermatol Ther. 2022;35(10):e15769. doi:10.1111/dth.15769
   PubMed Web of Science ®Google Scholar
• Almasi-Nasrabadi M, Ayyalaraju RS, Sharma A, et al. New onset pemphigus foliaceus following AstraZeneca COVID −19 vaccination. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18484
   PubMed Web of Science ®Google Scholar
• Corrá A, Barei F, Genovese G, et al. Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019. J Dermatol. 2022. doi:10.1111/1346-8138.16554
   PubMed Web of Science ®Google Scholar
• Solimani F, Mansour Y, Didona D, et al. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. J Eur Acad Dermatol Venereol. 2021;35(10):e649–51. doi:10.1111/jdv.17480
   PubMed Web of Science ®Google Scholar
• Martora F, Battista T, Nappa P, et al. Pemphigus vulgaris and COVID-19 vaccination: management and treatment. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15374
   Web of Science ®Google Scholar
• Maronese CA, Caproni M, Moltrasio C, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian multicentre study. Front Med. 2022;9:841506. doi:10.3389/fmed.2022.841506
   Web of Science ®Google Scholar
• Maronese CA, Di Zenzo G, Genovese G, et al. Reply to “New-onset bullous pemphigoid after inactivated Covid-19 vaccine: synergistic effect of the Covid-19 vaccine and vildagliptin”. Dermatol Ther. 2022;35:e15496. doi:10.1111/dth.15496
   PubMed Web of Science ®Google Scholar
• Hali FS, Araqi LJ, Marnissi F, et al. Autoimmune bullous dermatosis following COVID-19 vaccination: a series of five cases. Cureus. 2022;14:e23127. doi:10.7759/cureus.23127
   PubMed Web of Science ®Google Scholar
• Gambichler T, Hamdani N, Budde H, et al. Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2022;186(4):728–731. doi:10.1111/bjd.20890
   PubMed Web of Science ®Google Scholar
• Shanshal M. Dyshidrosiform bullous pemphigoid triggered by COVID-19 vaccination. Cureus. 2022;14:e26383. doi:10.7759/cureus.26383
   PubMed Web of Science ®Google Scholar
• Desai AD, Shah R, Haroon A, et al. Bullous pemphigoid following the moderna mRNA-1273 vaccine. Cureus. 2022;14:e24126. doi:10.7759/cureus.24126
   PubMed Web of Science ®Google Scholar
• Fu P-A, Chen C-W, Hsu Y-T, et al. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination. J Formosan Med Assoc. 2022;121(9):1872–1876. doi:10.1016/j.jfma.2022.02.017
   PubMed Web of Science ®Google Scholar
• Alshammari F, Abuzied Y, Korairi A, et al. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: a case report. Ann Med Surg. 2022;75:103420. doi:10.1016/j.amsu.2022.103420
   PubMed Web of Science ®Google Scholar
• Hung W-K, Chi C-C. Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2022;36:e407–e409. doi:10.1111/jdv.17955
   PubMed Web of Science ®Google Scholar
• Pauluzzi M, Stinco G, Errichetti E. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review. J Eur Acad Dermatol Venereol. 2022;36:e257–e259. doi:10.1111/jdv.17891
   PubMed Web of Science ®Google Scholar
• Dell’Antonia M, Anedda S, Usai F, et al. Bullous pemphigoid triggered by COVID-19 vaccine: rapid resolution with corticosteroid therapy. Dermatol Ther. 2022;35:e15208. doi:10.1111/dth.15208
   PubMed Web of Science ®Google Scholar
• Pérez-López I, Moyano-Bueno D, Ruiz-Villaverde R. Bullous pemphigoid and COVID-19 vaccine. Med Clin. 2021;157(10):e333–e334. doi:10.1016/j.medcli.2021.05.005
   PubMed Web of Science ®Google Scholar
• Agharbi F-Z, Eljazouly M, Basri G, et al. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine. Ann Dermatol Venereol. 2022;149:56–57. doi:10.1016/j.annder.2021.07.008
   PubMed Web of Science ®Google Scholar
• Young J, Mercieca L, Ceci M, et al. A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine. J Eur Acad Dermatol Venereol. 2022;36(1):e13–e16. doi:10.1111/jdv.17676
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kosano M, Sakai Y, et al. Case of bullous pemphigoid following coronavirus disease 2019 vaccination. J Dermatol. 2021;48(12):e606–e607. doi:10.1111/1346-8138.16170
   PubMed Web of Science ®Google Scholar
• Paolino G, Campochiaro C, Di Nicola MR, et al. Generalized morphea after COVID-19 vaccines: a case series. J Eur Acad Dermatol Venereol. 2022;36:e680–e682. doi:10.1111/jdv.18249
   PubMed Web of Science ®Google Scholar
• Antoñanzas J, Rodríguez-Garijo N, Estenaga Á, et al. Generalized morphea following the COVID vaccine: a series of two patients and a bibliographic review. Dermatol Ther. 2022;35(9):e15709. doi:10.1111/dth.15709
   PubMed Web of Science ®Google Scholar
• Oh DAQ, Heng YK, Tee S-I. Morphoea following COVID-19 Vaccination. Clin Exp Dermatol. 2022. doi:10.1111/ced.15349
   Web of Science ®Google Scholar
• Metin Z, Celepli P. A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins. Int J Dermatol. 2022;61:639–641. doi:10.1111/ijd.16062
   PubMed Web of Science ®Google Scholar
• Aryanian Z, Balighi K, Hatami P, et al. Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection. Clin Case Rep. 2022;10(4):e05667. doi:10.1002/ccr3.5667
   PubMed Web of Science ®Google Scholar
• Martora F, Battista T, Ruggiero A, et al. Reply to “Morphoea following COVID-19 Vaccination”. Clin Exp Dermatol. 2022. doi:10.1111/ced.15396
   Web of Science ®Google Scholar
• Temiz SA, Abdelmaksoud A, Dursun R, et al. Pityriasis rosea following SARS-CoV-2 vaccination: a case series. J Cosmet Dermatol. 2021;20(10):3080–3084. doi:10.1111/jocd.14372
   PubMed Web of Science ®Google Scholar
• Ramot Y, Nanova K, Faitatziadou S-M, et al. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2. J der Deutschen Dermatologischen Gesellschaft. 2022;20:1123–1124.
   Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Khattab E, Christaki E, Pitsios C. Pityriasis rosea induced by COVID-19 vaccination. Eur J Case Rep Intern Med. 2022;9(2):3164.
   Google Scholar
• Cyrenne BM, Al-Mohammedi F, DeKoven JG, et al. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol. 2021;35:e546–e548. doi:10.1111/jdv.17342
   PubMed Web of Science ®Google Scholar
• Valk B, Bender B. Pityriasis rosea associated with COVID-19 vaccination: a common rash following administration of a novel vaccine. Cutis. 2021;108(6):317–318. doi:10.12788/cutis.0411
   PubMed Web of Science ®Google Scholar
• Buckley JE, Landis LN, Rapini RP. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: a case report and review of the literature. JAAD Int. 2022;7:164–168. doi:10.1016/j.jdin.2022.01.009
   PubMedGoogle Scholar
• Wang C-S, Chen -H-H, Liu S-H. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. J Formosan Med Assoc. 2022;121:1003–1007. doi:10.1016/j.jfma.2021.12.028
   PubMed Web of Science ®Google Scholar
• Shin SH, Hong JK, Hong SA, et al. Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination. Int J Infect Dis. 2022;114:88–89.
   PubMed Web of Science ®Google Scholar
• Bostan E, Jarbou A. Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. J Med Virol. 2022;94:814–816. doi:10.1002/jmv.27364
   PubMed Web of Science ®Google Scholar
• Leerunyakul K, Pakornphadungsit K, Suchonwanit P. Case report: pityriasis rosea-like Eruption following COVID-19 vaccination. Front med. 2021;8:752443. doi:10.3389/fmed.2021.752443
   Web of Science ®Google Scholar
• Cohen OG, Clark AK, Milbar H, et al. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. Hum Vaccin Immunother. 2021;17(11):4097–4098. doi:10.1080/21645515.2021.1963173
   PubMed Web of Science ®Google Scholar
• Dormann H, Grummt S, Karg M. Pityriasis rosea as a possible complication of vaccination against COVID-19. Dtsch Arztebl Int. 2021;118(25):431. doi:10.3238/arztebl.m2021.0257
   PubMedGoogle Scholar
• Bin Rubaian NF, Almuhaidib SR, Aljarri SA, et al. Pityriasis rosea following pfizer-BioNTech vaccination in an adolescent girl. Cureus. 2022;14:e27108. doi:10.7759/cureus.27108
   PubMed Web of Science ®Google Scholar
• Fenner B, Marquez JL, Pham M, et al. Inverse pityriasis rosea secondary to COVID-19 vaccination. Proceedings (Baylor University. Medical Center); 2022: 342–343.
   Google Scholar
• Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesque D, et al. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35:e721–e722. doi:10.1111/jdv.17498
   PubMed Web of Science ®Google Scholar
• Abdullah L, Hasbani D, Kurban M, et al. Pityriasis rosea after mRNA COVID-19 vaccination. Int J Dermatol. 2021;60(9):1150–1151. doi:10.1111/ijd.15700
   PubMed Web of Science ®Google Scholar
• Carballido Vázquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. Br J Dermatol. 2021;185(2):e34. doi:10.1111/bjd.20143
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fornaro L, et al. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions after COVID-19 vaccines. JAAD int. 2022;9:127. doi:10.1016/j.jdin.2022.03.018
   PubMedGoogle Scholar
• Naoum C, Hartmann M. Herpes zoster reactivation after COVID-19 vaccination - A retrospective case series of 22 patients. Int J Dermatol. 2022;61:628–629. doi:10.1111/ijd.16116
   PubMed Web of Science ®Google Scholar
• Agrawal S, Verma K, Verma I, et al. Reactivation of herpes zoster virus after COVID-19 vaccination: is there any association? Cureus. 2022;14(5):e25195. doi:10.7759/cureus.25195
   PubMed Web of Science ®Google Scholar
• Monastirli A, Pasmatzi E, Badavanis G, et al. Herpes Zoster after mRNA COVID-19 vaccination: a case series. Skinmed. 2022;20(4):284–288.
   PubMedGoogle Scholar
• Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology. 2021;60(SI):SI90–5. doi:10.1093/rheumatology/keab345
   PubMed Web of Science ®Google Scholar
• Vastarella M, Picone V, Martora F, et al. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series. J Eur Acad Dermatol Venereol. 2021;35(12):e845–e846. doi:10.1111/jdv.17576
   PubMed Web of Science ®Google Scholar
• Palanivel JA. Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? J Cosmet Dermatol. 2021;20:3376–3377. doi:10.1111/jocd.14470
   PubMed Web of Science ®Google Scholar
• Vallianou NG, Tsilingiris D, Karampela I, et al. Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: a two-vaccine related event? Metab Open. 2022;13:100171. doi:10.1016/j.metop.2022.100171
   PubMedGoogle Scholar
• Jiang Z-H, Wong L-S, Lee C-H, et al. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. Indian J Dermatol Venereol Leprol. 2022;88:445. doi:10.25259/IJDVL_819_2021
   PubMed Web of Science ®Google Scholar
• You I-C, Ahn M, Cho N-C, Case A. Report of herpes zoster ophthalmicus and meningitis after COVID-19 vaccination. J Korean Med Sci. 2022;37:e165. doi:10.3346/jkms.2022.37.e165
   PubMed Web of Science ®Google Scholar
• Tanizaki R, Miyamatsu Y. Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient. IDCases. 2022;29:e01563. doi:10.1016/j.idcr.2022.e01563
   PubMed Web of Science ®Google Scholar
• Russo R, Cozzani E, Micalizzi C, et al. Chilblain-like lesions after COVID-19 vaccination: a case series. Acta Derm Venereol. 2022;102:adv00711. doi:10.2340/actadv.v102.2076
   PubMed Web of Science ®Google Scholar
• Paparella R, Tarani L, Properzi E, et al. Chilblain-like lesions onset during SARS-CoV-2 infection in a COVID-19-vaccinated adolescent: case report and review of literature. Ital J Pediatr. 2022;48(1):93. doi:10.1186/s13052-022-01296-5
   PubMed Web of Science ®Google Scholar
• Davido B, Mascitti H, Fortier-Beaulieu M, et al. “Blue toes” following vaccination with the BNT162b2 mRNA COVID-19 vaccine. J Travel Med. 2021;28(4). doi:10.1093/jtm/taab024
   Web of Science ®Google Scholar
• Lopez S, Vakharia P, Vandergriff T, et al. Pernio after COVID-19 vaccination. Br J Dermatol. 2021;185(2):445–447. doi:10.1111/bjd.20404
   PubMed Web of Science ®Google Scholar
• Pileri A, Guglielmo A, Raone B, et al. Chilblain lesions after COVID-19 mRNA vaccine. Br J Dermatol. 2021;185(1):e3. doi:10.1111/bjd.20060
   PubMed Web of Science ®Google Scholar
• Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. J Eur Acad Dermatol Venereol. 2021;35:e493–e494. doi:10.1111/jdv.17320
   PubMed Web of Science ®Google Scholar
• Pérez-López I, Gil-Villalba A, Ruiz-Villaverde R. Perniosis-like lesions after vaccination with mRNA against COVID-19. Med Clin (Barc). 2022;158:189–190. doi:10.1016/j.medcli.2021.05.016
   PubMed Web of Science ®Google Scholar
• Cameli N, Silvestri M, Mariano M, et al. Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):e725–e727. doi:10.1111/jdv.17500
   PubMed Web of Science ®Google Scholar
• Kha C, Itkin A. New-onset chilblains in close temporal association to mRNA-1273 vaccination. JAAD Case Rep. 2021;12:12–14. doi:10.1016/j.jdcr.2021.03.046
   PubMedGoogle Scholar
• Lesort C, Kanitakis J, Donzier L, et al. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that “COVID toes” are due to the immune reaction to SARS-CoV-2. J Eur Acad Dermatol Venereol. 2021;35:e630–2. doi:10.1111/jdv.17451
   PubMed Web of Science ®Google Scholar
• Kaminetsky J, Rudikoff D. New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination. Clin Case Rep. 2021;9:e04865. doi:10.1002/ccr3.4865
   PubMed Web of Science ®Google Scholar
• Militello M, Ambur AB, Steffes W. Vitiligo possibly triggered by COVID-19 vaccination. Cureus. 2022;14:e20902. doi:10.7759/cureus.20902
   PubMed Web of Science ®Google Scholar
• Singh R, Cohen JL, Astudillo M, et al. Vitiligo of the arm after COVID-19 vaccination. JAAD Case Rep. 2022;28:142–144. doi:10.1016/j.jdcr.2022.06.003
   PubMedGoogle Scholar
• Nicolaidou E, Vavouli C, Koumprentziotis I-A, et al. New-onset vitiligo after COVID −19 mRNA vaccination: a causal association? J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18513
   Web of Science ®Google Scholar
• Flores-Terry MÁ, García-Arpa M, Santiago-Sánchez Mateo JL, et al. [Facial vitiligo after SARS-CoV-2 vaccination]. Actas Dermosifiliogr. 2022;113(7):721. Spanish. doi:10.1016/j.ad.2022.01.030
   PubMed Web of Science ®Google Scholar
• Bukhari AE. New-onset of vitiligo in a child following COVID-19 vaccination. JAAD Case Rep. 2022;22:68–69. doi:10.1016/j.jdcr.2022.02.021
   PubMedGoogle Scholar
• Uğurer E, Sivaz O, Kıvanç Altunay İ, et al. Newly-developed vitiligo following COVID-19 mRNA vaccine. J Cosmet Dermatol. 2022;21(4):1350–1351. doi:10.1111/jocd.14843
   PubMed Web of Science ®Google Scholar
• Ciccarese G, Drago F, Boldrin S, et al. Sudden onset of vitiligo after COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15196. doi:10.1111/dth.15196
   PubMed Web of Science ®Google Scholar
• López Riquelme I, Fernández Ballesteros MD, Serrano Ordoñez A, et al. COVID −19 and autoimmune phenomena: vitiligo after AstraZeneca vaccine. Dermatol Ther. 2022;35:e15502. doi:10.1111/dth.15502
   PubMed Web of Science ®Google Scholar
• Okan G, Vural P. Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine. Dermatol Ther. 2022;35:e15280. doi:10.1111/dth.15280
   PubMed Web of Science ®Google Scholar
• Caroppo F, Deotto ML, Tartaglia J, et al. Vitiligo worsened following the second dose of mRNA SARS-CoV −2 vaccine. Dermatol Ther. 2022;35:e15434. doi:10.1111/dth.15434
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, et al. Skin reaction after SARS-CoV −2 vaccines Reply to ‘cutaneous adverse reactions following SARS-CoV −2 vaccine booster dose: a real-life multicentre experience’. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18531
   Web of Science ®Google Scholar
• McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. doi:10.1016/j.jaad.2021.03.092
   PubMed Web of Science ®Google Scholar
• Hlaca N, Zagar T, Kastelan M, et al. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine [published online ahead of print, 2022 Aug 27]. Dermatol Ther;2022. e15791. doi:10.1111/dth.15791
   PubMed Web of Science ®Google Scholar
• Annabi E, Dupin N, Sohier P, et al. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol. 2021;35:e847–e850. doi:10.1111/jdv.17578
   PubMed Web of Science ®Google Scholar
• Hunjan MK, Roberts C, Karim S, et al. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol. 2022;47:188–190. doi:10.1111/ced.14878
   PubMed Web of Science ®Google Scholar
• Fiorillo G, Pancetti S, Cortese A, et al. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination. J Autoimmun. 2022;127:102783. doi:10.1016/j.jaut.2021.102783
   PubMed Web of Science ®Google Scholar
• Avallone G, Quaglino P, Cavallo F, et al. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol. 2022;61(10):1187–1204. doi:10.1111/ijd.16063
   PubMed Web of Science ®Google Scholar
• Gambichler T, Scheel CH, Arafat Y, et al. Erythrodermic pityriasis rubra pilaris after SARS-CoV −2 vaccination with concomitant COVID −19 infection. J Eur Acad Dermatol Venereol. 2022;36:e675–6. doi:10.1111/jdv.18214
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Gabros S, Friefeld S, et al. Generalized granuloma annulare after COVID-19 vaccination. JAAD Case Rep. 2022;25:18–21. doi:10.1016/j.jdcr.2022.05.003
   PubMedGoogle Scholar
• Martora F, Villani A, Battista T, et al. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15414
   Web of Science ®Google Scholar
• Camela E, Scalvenzi M, Megna M, et al. Reply to “A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination” by Manaa et al. Dermatol Ther. 2022;35(7):e15881.
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Guerrasio G, et al. Reply to ‘A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID −19 vaccine’. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18646
   Web of Science ®Google Scholar
• Martora F, Fornaro L, Picone V, et al. Herpes zoster and alopecia areata following mRNA BNT162b2 COVID-19 vaccine: controversial immune effects. J Cosmet Dermatol. 2022. doi:10.1111/jocd.15465
   Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, et al. Impact of the COVID −19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic [published online ahead of print, 2022 Aug 26]. Dermatol Ther;2022. e15786. doi:10.1111/dth.15786
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fornaro F, et al. Reply to ‘Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity’ by R. Molinier et al. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.18512
   Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi:10.1007/s12325-022-02044-1
   PubMed Web of Science ®Google Scholar
• Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758–760. doi:10.4103/ijdvl.IJDVL_92_18
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022;23(12):6388. doi:10.3390/ijms23126388
   PubMed Web of Science ®Google Scholar
• Farr MA, Duvic M, Joshi TP. Teledermatology during COVID-19: an updated review. Am J Clin Dermatol. 2021;22(4):467–475. doi:10.1007/s40257-021-00601-y
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Megna M, Fabbrocini G, et al. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022. doi:10.1111/ced.15286
   Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, et al. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279–283. doi:10.1093/ageing/afaa274
   PubMed Web of Science ®Google Scholar
• Liu Q, Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132. doi:10.1186/s40249-021-00915-3
   PubMed Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, et al. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022. doi:10.1111/jocd.15331
   Web of Science ®Google Scholar